{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_2664", "batch_size": 200, "batch_pos": 75, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment describes advantages, not the threat's impact, without high-potency language.", "method": "llm_batch", "batch_id": "batch_2_14808", "batch_size": 200, "batch_pos": 67, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"hop_idx": 3, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_3_8472", "batch_size": 200, "batch_pos": 42, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment describes vaccine technology advantages.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_3_8472_r1", "batch_size": 200, "batch_pos": 42, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "No loaded rhetorical question present.", "method": "llm_batch", "batch_id": "batch_4_18184", "batch_size": 200, "batch_pos": 41, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment reports advantages of technology, not a calming cue.", "method": "llm_batch", "batch_id": "batch_5_16300", "batch_size": 200, "batch_pos": 40, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No 'minimiser + scale contrast' found.", "method": "llm_batch", "batch_id": "batch_6_17420", "batch_size": 200, "batch_pos": 25, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_15972", "batch_size": 200, "batch_pos": 20, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Describes the advantages/capabilities of a technology used for preparedness: 'offers advantages in efficacy, speed... scalability, and reliability'.", "method": "llm_batch", "batch_id": "batch_8_11304", "batch_size": 200, "batch_pos": 144, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
